Chinese General Practice ›› 2025, Vol. 28 ›› Issue (18): 2222-2227.DOI: 10.12114/j.issn.1007-9572.2024.0309
Special Issue: 高血压最新文章合辑
• Article • Previous Articles Next Articles
Received:
2024-05-10
Revised:
2024-09-10
Published:
2025-06-20
Online:
2025-04-25
Contact:
YANG Li
通讯作者:
杨莉
作者简介:
作者贡献:
何燕提出主要研究目标,负责撰写并修订论文;崔赛仙负责研究的构思与设计;胡阳、倪晴负责研究的实施;甘露路、代安妮进行数据的收集与整理;刘茜进行统计学处理;刘师节进行图、表的绘制与展示;杨莉负责文章的质量控制与审查,对文章整体负责,监督管理。
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0309
组别 | 例数 | 性别(男/女) | 年龄( | BMI[M(P25,P75),kg/m2] | 腹围( | HB( | RBC( | FPG[M(P25,P75),mmol/L] |
---|---|---|---|---|---|---|---|---|
轻度组 | 103 | 61/42 | 52.52±11.68 | 24.02(22.46,26.49) | 89.14±10.86 | 153.41±17.23 | 4.99±0.51 | 5.24(4.79,5.74) |
中度组 | 187 | 133/54 | 52.74±12.63 | 25.10(23.51,27.70)a | 94.01±11.10a | 154.10±17.36 | 5.03±0.54 | 5.34(4.91,6.03) |
重度组 | 203 | 151/52ab | 52.04±12.27 | 27.71(25.05,30.07)ab | 98.99±9.39ab | 154.64±16.55 | 5.11±0.59 | 5.25(4.88,6.16) |
检验统计量值 | 7.211c | 0.161 | 61.621d | 18.862 | 0.164 | 1.590 | 2.362d | |
P值 | 0.027 | 0.851 | <0.001 | <0.001 | 0.849 | 0.205 | 0.307 | |
组别 | ALT[M(P25,P75),U/L] | AST[M(P25,P75),U/L] | eGFR[ | UA( | TC( | LDL-C( | HDL-C( | TG[M(P25,P75),mmol/L] |
轻度组 | 23(18,33) | 22(18,28) | 93.75±22.40 | 374.44±93.62 | 4.81±0.99 | 2.92±0.83 | 1.17±0.27 | 1.51(1.08,2.46) |
中度组 | 25(16,40) | 21(18,26) | 96.16±19.46 | 392.35±109.02 | 4.63±0.97 | 2.81±0.75 | 1.08±0.27a | 1.81(1.27,2.55) |
重度组 | 27(20,43)ab | 23(19,28) | 94.25±22.08 | 412.28±94.34ab | 4.49±0.95a | 2.72±0.78 | 1.02±0.23a | 1.89(1.28,2.65) |
检验统计量值 | 6.056d | 2.654d | 0.545 | 4.681 | 3.464 | 2.091 | 11.138 | 5.646d |
P值 | 0.048 | 0.265 | 0.451 | 0.010 | 0.032 | 0.125 | <0.001 | 0.059 |
组别 | K( | Na( | 24 h尿钠排泄量( | 24 h尿钾( | 24 h尿钠钾比( | 24 hUALB[M(P25,P75),g/24 h] | 24 h估测摄盐量( | |
轻度组 | 4.07±0.41 | 140.72±2.58 | 158.58±51.83 | 40.59±13.65 | 4.28±1.82 | 0.16(0.13,0.23) | 9.24±3.03 | |
中度组 | 3.99±0.40 | 140.92±2.19 | 177.98±67.29a | 44.19±18.94 | 4.41±1.78 | 0.19(0.14,0.25)a | 10.41±3.91 a | |
重度组 | 3.96±0.40 | 140.82±2.64 | 198.85±67.27ab | 46.19±18.47ab | 4.69±1.77 | 0.22(0.15,0.31)ab | 11.63±3.93 ab | |
检验统计量值 | 2.578 | 0.196 | 13.317 | 3.147 | 2.177 | 15.282d | 13.320 | |
P值 | 0.077 | 0.822 | <0.001 | 0.044 | 0.144 | <0.001 | <0.001 |
Table 1 Comparison of clinical data among three groups of patients with OSA-associated hypertension
组别 | 例数 | 性别(男/女) | 年龄( | BMI[M(P25,P75),kg/m2] | 腹围( | HB( | RBC( | FPG[M(P25,P75),mmol/L] |
---|---|---|---|---|---|---|---|---|
轻度组 | 103 | 61/42 | 52.52±11.68 | 24.02(22.46,26.49) | 89.14±10.86 | 153.41±17.23 | 4.99±0.51 | 5.24(4.79,5.74) |
中度组 | 187 | 133/54 | 52.74±12.63 | 25.10(23.51,27.70)a | 94.01±11.10a | 154.10±17.36 | 5.03±0.54 | 5.34(4.91,6.03) |
重度组 | 203 | 151/52ab | 52.04±12.27 | 27.71(25.05,30.07)ab | 98.99±9.39ab | 154.64±16.55 | 5.11±0.59 | 5.25(4.88,6.16) |
检验统计量值 | 7.211c | 0.161 | 61.621d | 18.862 | 0.164 | 1.590 | 2.362d | |
P值 | 0.027 | 0.851 | <0.001 | <0.001 | 0.849 | 0.205 | 0.307 | |
组别 | ALT[M(P25,P75),U/L] | AST[M(P25,P75),U/L] | eGFR[ | UA( | TC( | LDL-C( | HDL-C( | TG[M(P25,P75),mmol/L] |
轻度组 | 23(18,33) | 22(18,28) | 93.75±22.40 | 374.44±93.62 | 4.81±0.99 | 2.92±0.83 | 1.17±0.27 | 1.51(1.08,2.46) |
中度组 | 25(16,40) | 21(18,26) | 96.16±19.46 | 392.35±109.02 | 4.63±0.97 | 2.81±0.75 | 1.08±0.27a | 1.81(1.27,2.55) |
重度组 | 27(20,43)ab | 23(19,28) | 94.25±22.08 | 412.28±94.34ab | 4.49±0.95a | 2.72±0.78 | 1.02±0.23a | 1.89(1.28,2.65) |
检验统计量值 | 6.056d | 2.654d | 0.545 | 4.681 | 3.464 | 2.091 | 11.138 | 5.646d |
P值 | 0.048 | 0.265 | 0.451 | 0.010 | 0.032 | 0.125 | <0.001 | 0.059 |
组别 | K( | Na( | 24 h尿钠排泄量( | 24 h尿钾( | 24 h尿钠钾比( | 24 hUALB[M(P25,P75),g/24 h] | 24 h估测摄盐量( | |
轻度组 | 4.07±0.41 | 140.72±2.58 | 158.58±51.83 | 40.59±13.65 | 4.28±1.82 | 0.16(0.13,0.23) | 9.24±3.03 | |
中度组 | 3.99±0.40 | 140.92±2.19 | 177.98±67.29a | 44.19±18.94 | 4.41±1.78 | 0.19(0.14,0.25)a | 10.41±3.91 a | |
重度组 | 3.96±0.40 | 140.82±2.64 | 198.85±67.27ab | 46.19±18.47ab | 4.69±1.77 | 0.22(0.15,0.31)ab | 11.63±3.93 ab | |
检验统计量值 | 2.578 | 0.196 | 13.317 | 3.147 | 2.177 | 15.282d | 13.320 | |
P值 | 0.077 | 0.822 | <0.001 | 0.044 | 0.144 | <0.001 | <0.001 |
组别 | 例数 | AHI[M(P25,P75),次/h] | LSaO2[M(P25,P75),%] | MSaO2[M(P25,P75),%] | 24 hMSBP( | 24 hMDBP( | dMSBP( | dMDBP( | nMSBP( | nMDBP( |
---|---|---|---|---|---|---|---|---|---|---|
轻度组 | 103 | 10.20(7.40,12.90) | 80.00(78.50,86.00) | 93.00(91.50,94.00) | 131±15 | 84±12 | 133±16 | 85±12 | 127±16 | 80±12 |
中度组 | 187 | 22.30(18.83,26.48)a | 77.00(71.50,81.25)a | 90.00(87.00,93.00)a | 133±14 | 84±11 | 135±15 | 85±12 | 128±16 | 80±12 |
重度组 | 203 | 45.60(40.40,63.50)ab | 75.00(65.00,79.00)ab | 90.00(87.00,92.00)a | 135±18a | 86±13 | 136±18 | 87±13 | 130±19ab | 82±14 |
F(H)值 | 414.811c | 73.117c | 61.436c | 1.522 | 1.823 | 1.222 | 1.272 | 1.640 | 1.006 | |
P值 | <0.001 | <0.001 | <0.001 | 0.220 | 0.163 | 0.295 | 0.281 | 0.045 | 0.367 |
Table 2 Comparison of PSG and dynamic blood pressure data among three groups of patients with OSA-associated hypertension
组别 | 例数 | AHI[M(P25,P75),次/h] | LSaO2[M(P25,P75),%] | MSaO2[M(P25,P75),%] | 24 hMSBP( | 24 hMDBP( | dMSBP( | dMDBP( | nMSBP( | nMDBP( |
---|---|---|---|---|---|---|---|---|---|---|
轻度组 | 103 | 10.20(7.40,12.90) | 80.00(78.50,86.00) | 93.00(91.50,94.00) | 131±15 | 84±12 | 133±16 | 85±12 | 127±16 | 80±12 |
中度组 | 187 | 22.30(18.83,26.48)a | 77.00(71.50,81.25)a | 90.00(87.00,93.00)a | 133±14 | 84±11 | 135±15 | 85±12 | 128±16 | 80±12 |
重度组 | 203 | 45.60(40.40,63.50)ab | 75.00(65.00,79.00)ab | 90.00(87.00,92.00)a | 135±18a | 86±13 | 136±18 | 87±13 | 130±19ab | 82±14 |
F(H)值 | 414.811c | 73.117c | 61.436c | 1.522 | 1.823 | 1.222 | 1.272 | 1.640 | 1.006 | |
P值 | <0.001 | <0.001 | <0.001 | 0.220 | 0.163 | 0.295 | 0.281 | 0.045 | 0.367 |
项目 | r(rs)值 | P值 |
---|---|---|
AHI | 0.223a | <0.001 |
LSaO2 | -0.103a | 0.023 |
MSaO2 | -0.090a | 0.048 |
BMI | 0.226a | <0.001 |
年龄 | -0.098 | 0.032 |
性别(男性) | 0.177a | <0.001 |
24 hMSBP | 0.126 | 0.008 |
24 hMDBP | 0.109 | 0.020 |
Table 3 Correlation analysis of 24-hour urinary sodium excretion with PSG indicators and clinical features in patients with OSA-associated hypertension
项目 | r(rs)值 | P值 |
---|---|---|
AHI | 0.223a | <0.001 |
LSaO2 | -0.103a | 0.023 |
MSaO2 | -0.090a | 0.048 |
BMI | 0.226a | <0.001 |
年龄 | -0.098 | 0.032 |
性别(男性) | 0.177a | <0.001 |
24 hMSBP | 0.126 | 0.008 |
24 hMDBP | 0.109 | 0.020 |
项目 | B | SE | β | t值 | P值 | VIF |
---|---|---|---|---|---|---|
常数 | 23.055 | 31.182 | 0.739 | 0.460 | ||
AHI | 0.419 | 0.141 | 0.138 | 2.964 | 0.003 | 1.144 |
24 hMSBP | 0.406 | 0.191 | 0.114 | 2.128 | 0.034 | 1.026 |
BMI | 2.873 | 0.829 | 0.166 | 3.466 | 0.001 | 1.145 |
性别 | 23.580 | 6.641 | 0.160 | 3.551 | <0.001 | 1.009 |
Table 4 Multivariate linear regression analysis of influencing factors for 24-h urinary sodium in patients with OSA-associated hypertension
项目 | B | SE | β | t值 | P值 | VIF |
---|---|---|---|---|---|---|
常数 | 23.055 | 31.182 | 0.739 | 0.460 | ||
AHI | 0.419 | 0.141 | 0.138 | 2.964 | 0.003 | 1.144 |
24 hMSBP | 0.406 | 0.191 | 0.114 | 2.128 | 0.034 | 1.026 |
BMI | 2.873 | 0.829 | 0.166 | 3.466 | 0.001 | 1.145 |
性别 | 23.580 | 6.641 | 0.160 | 3.551 | <0.001 | 1.009 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
王云,何燕,刘师节,等. 阻塞性睡眠呼吸暂停低通气综合征与糖脂代谢紊乱的机制研究进展[J]. 中国全科医学,2022,25(2):243-247. DOI:10.12114/j.issn.1007-9572.2021.01.311.
|
[8] |
|
[9] |
|
[10] |
|
[11] |
国家卫生健康委高血压诊疗研究重点实验室学术委员会,新疆维吾尔自治区人民医院高血压中心. 2023阻塞性睡眠呼吸暂停相关性高血压临床诊断和治疗专家共识 [J]. 中华高血压杂志,2023,31(12):1142-1155. DOI:10.16439/j.issn.1673-7245.2023.12.003.
|
[12] |
孙宁玲,牟建军,李玉明. 高血压患者盐摄入量评估和血压管理临床流程专家建议书[J]. 中华高血压杂志,2016,24(8):727-728.
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[1] | WU Wenjun, WEI Jingjing, LI Xue, REN Hongjie, YU Rui, PENG Guangcao, ZHU Mingjun. Regularity of Prescriptions for Coronary Heart Disease with Hypertension Based on Latent Structure and Association Rules [J]. Chinese General Practice, 2025, 28(30): 3787-3795. |
[2] | BAI Jiaxin, CHEN Yu, ZHOU Yiheng, LIU Lidi, YANG Rong, YAO Yi, YUAN Bo, ZHANG Yonggang, LEI Yi, ZENG Rui, JIA Yu, LIAO Xiaoyang. Assessment and Treatment of Early-onset Hypertension: Position Statement of the British and Irish Hypertension Association and Its Implications for Clinical Management of Early-onset Hypertension in China [J]. Chinese General Practice, 2025, 28(30): 3741-3746. |
[3] | QIN Bangguo, SUN Jin, LI Man, QIU Jiaojiao, CHENG Bokai, ZHU Ping, WANG Shuxia. Relationship between Non-high-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol Ratio and Left Ventricular Hypertrophy in a Community-based Hypertensive Population [J]. Chinese General Practice, 2025, 28(30): 3753-3760. |
[4] | HAN Xiao, LI Qiyu, GE Pu, FAN Siyuan, LIU Diyue, WU Yibo, ZHANG Qingshuang. The Impact of Behavioral Lifestyle on Quality of Life in Hypertensive Patients [J]. Chinese General Practice, 2025, 28(26): 3248-3258. |
[5] | YU Zizi, LIU Duli, LI Ximin, RUAN Chunyi, YIN Xiangyang, CAI Le. Analysis of the Prevalence and Self-management of Hypertension and Its Influencing Factors in Rural [J]. Chinese General Practice, 2025, 28(25): 3137-3143. |
[6] | TANG Shangfeng, HUANG Yangzhen, PAN Yangyang, ZHENG Yanxi, XIONG Zhongbao, ZHANG Kangkang, SONG Jia, WEI Yilin, WANG Chunying, DONG Heng, CHEN Manwei, QING Hua. Specification for the Integration of Healthcare and Prevention Services in Hypertension at the Primary Level [J]. Chinese General Practice, 2025, 28(25): 3089-3095. |
[7] | FAN Boyang, ZHANG Yu, SUN Wenning, ZHANG Huifang, WANG Yingjie, ZHANG Ao, ZHAO Yang, WANG Haipeng. Study of Behavioral Intention and Influencing Factors of Integrated Medical and Preventive Care Provided by Grassroots Doctors for Patients with Chronic Diseases [J]. Chinese General Practice, 2025, 28(25): 3144-3150. |
[8] | YAN Fanghong, PENG Guotian, ZHANG Guoli, SUN Ruiyi, MA Yuxia, HAN Lin. Matching Analysis of the Content of Chronic Disease Management for the Elderly in Medical Union: Based on the Perspective of "Guidance-Practice-Need" [J]. Chinese General Practice, 2025, 28(25): 3119-3126. |
[9] | WEI Yunhong, YANG Li, WANG Yulu, YE Qiufang, DAI Anni, HE Yan. Study on Cardiopulmonary Function During Different Exercise Stages in Patients with Obesity-related Hypertension [J]. Chinese General Practice, 2025, 28(24): 2972-2978. |
[10] | HE Jinyu, ZHULIDUZI Jiesisibieke, ZHANG Ning, LIU Min, LIANG Wannian. Research on Blood Pressure Control and Its Determinants Among Hypertensive Patients Under Standardized Management in China: Status, Challenges, and Future Directions [J]. Chinese General Practice, 2025, 28(24): 2968-2971. |
[11] | BAI Xue, CHEN Qianqian, LI Jie. Innovative Practices in Chronic Disease Management: a New Model for Generalist-Specialist Combination Management of Diabetes and Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2841-2845. |
[12] | CHEN Youlan, LAN Yanqi, WU Ahua, ZHANG Haixia, HUANG Jiankang, GUO Zhinan. The Health Management Effect of Contracted Family Doctor Services under the Joint Management of Three Teachers in Xiamen City on Elderly Hypertensive Patients [J]. Chinese General Practice, 2025, 28(22): 2769-2775. |
[13] | LONG Chunxiao, LI Chenglu, FAN Yangdong, SHI Lei. Quantitative Analysis of Chronic Disease Prevention and Treatment Policy Texts in China: Three-dimensional Framework Based on Policy Tools, Policy Evolution and Policy Subjects [J]. Chinese General Practice, 2025, 28(20): 2457-2463. |
[14] | LI Liqing, YANG Sule, ZENG Chuanmei. Analysis of the Evolution Path and Development Trend of Research Hotspots in Chronic Disease Management in China [J]. Chinese General Practice, 2025, 28(19): 2321-2329. |
[15] | HAO Aihua, ZENG Ziying, JIN Aiqiong, TANG Lingling, ZHENG Zique, MA Jingtai, ZHAO Jianguo, ZENG Weilin, XIAO Jianpeng, NIE Hui, YANG Ying. Analysis of Factors Influencing Avoidable Hospitalization for Elderly Hypertensive Patients [J]. Chinese General Practice, 2025, 28(19): 2370-2375. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||